Type 2 Diabetes

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

TIMI Group investigators found the effects of dapagliflozin on cardiovascular risk in patients with diabetes were comparable in those with markers of CKD and those without markers of CKD at baseline.

Using data from nearly 1 million patients with type 2 diabetes in a commercial database, investigators provide a comprehensive of the impact race/ethnicity, gender, and income can have on the likelihood of receiving a prescription for SGLT2 inhibitors.

An analysis of the DECLARE-TIMI 58 trial indicates the cardiovascular benefit of dapagliflozin use in patients with diabetes was consistent regardless of baseline kidney function and suggests the effects could be independent of glucose reduction.

A new study on dapagliflozin use finds consistent risk reduction in treatment of patients with higher rates of kidney dysfunction.

A trial led by clinicians from Northwestern Medicine suggests the presence of ischemic leg symptoms could serve as a useful indicator for patients to help determine whether they will see a meaningful benefit from their walking program.

An analysis of the CLARIFY registry is providing clinicians with further insight into the impact of diabetes in patients with chronic coronary syndromes, particularly the increased risk of stroke, myocardial infarction, and cardiovascular death.

New data suggest injections of adipose-derived SVF cells could elicit wound closure in patients with nonhealing diabetic foot ulcers and, subsequently, reduce the need for amputation in this patient population.

An analysis of the CLARIFY registry suggests patients with chronic coronary syndromes were 3 times more likely than the general population to have diabetes and these patients were at a greater risk of multiple adverse outcomes compared to their counterparts without diabetes.

A case-controlled study of 60 patients in the United Kingdom found presence neuropathy contributes to fracture risk in patients with type 1 diabetes but found other factors play a role in the increased risk among these patients.

Results of a randomized clinical trial suggest treatment with high-frequency spinal cord stimulation added to conventional medical management could lead to pain relief and improvements in quality of life among patients with refractory peripheral diabetic neuropathy.

Many believed radiocontrast exposure could be linked to long-term kidney impairment.

An analysis of the DAPA-HF trial indicates the impact of dapagliflozin were consistent across both men and women receiving the SGLT2 inhibitor.

An analysis of 2-year data from the DRCR Retina Network's Protocol W study indicates anti-VEGF treatments can delay progression of NPDR to proliferative diabetic retinopathy but was not linked to improvements in visual acuity.

A subgroup analysis from DAPA-HF show the SGLT2 inhibitor provided efficacy regardless of HFrEF patient gender.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

A phase 2 trial examining the effects of daily semaglutide over a 72-week period suggests the GLP1-RA could help patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) achieve NASH resolution.

An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.

An expert physician in cardiology and metabolic management walks through a presentation on identifying, addressing, and continually treating for heightened cardiometabolic risk.

Juan Frias, MD, breaks down results of a post-hoc analysis of the AWARD-11 study examining expanded doses of dulaglutide according to baseline HbA1c levels.

Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.

The therapy could offer a therapeutic option with a better safety profile, investigators said.

Learn more about once-weekly basal insulin Fc from Eli Lilly and Company in this interview with the lead investigator from their phase 2 trial, which was presented at ENDO 2021.

The approval is based on results from Phase 3 trials showing high efficacy in adult and pediatric populations.

Zealand Pharma announced the US FDA approved dasiglucagon (Zegalogue) for treatment of severe hypoglycemia in patients with diabetes aged 6 and older and the injectable will be available as both an auto injector and a prefilled syringe.

A literature review of studies assessing SGLT2 inhibitor use in kidney transplant patients with diabetes suggests use did not impact graft function and was associated with improvements in glucose control and body weight.

A single-injection co-formulation of pramlitide and insulin may be a better alternative to separate administrations of both key treatments in adults with T1D, particularly following meals.

A majority of surveyed patients and providers want to continue telemedicine follow-up visits after the pandemic ends.

Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.

Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.